Patents by Inventor Philippe Lassalle

Philippe Lassalle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient by measuring endocan levels in blood
    Patent number: 9945873
    Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: April 17, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE DROIT ET DE LA SANTE LILLE 2, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE
    Inventor: Philippe Lassalle
  • MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT
    Publication number: 20150168399
    Abstract: An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 18, 2015
    Inventors: Nathalie DE FREITAS CAIRES, Philippe LASSALLE, Philippe HAUW
  • METHODS AND KITS FOR PREDICTING THE RISK OF RESPIRATORY FAILURE, RENAL FAILURE OR THROMBOPENIA IN A SEPTIC PATIENT BY MEASURING ENDOCAN LEVELS IN BLOOD
    Publication number: 20140017707
    Abstract: The present invention relates to methods and kits for predicting the risk of respiratory failure, renal failure or thrombopenia in a septic patient. More particularly, the present invention relates to a method for predicting the risk of having an organ failure selected from the group consisting of respiratory failure, renal failure and thrombopenia in a septic patient comprising a step consisting of measuring the concentration of endocan in a blood sample obtained from said septic patient.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 16, 2014
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Hospitalier Regional Universitaire de Lille, Universite de Droit et de la Sante Lille 2
    Inventor: Philippe Lassalle
  • MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT
    Publication number: 20120015387
    Abstract: An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1-116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa.
    Type: Application
    Filed: October 8, 2009
    Publication date: January 19, 2012
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT PASTEUR DE LILLE
    Inventors: Nathalie De Freitas Caires, Philippe Lassalle, Philippe Hauw
  • THE USE OF A NON-GLYCANATED POLYPEPTIDE FOR TREATING A CANCER
    Publication number: 20110301092
    Abstract: The use of a non-glycanated form of a polypeptide including an amino acid sequence having at least 90% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 and SEQ ID No 2 for manufacturing a medicament for preventing or treating a cancer.
    Type: Application
    Filed: October 24, 2008
    Publication date: December 8, 2011
    Applicant: INSTITUT PASTEUR DE LILLE
    Inventors: Philippe Lassalle, Bogdan Grigoriu, Florence Depontieu
  • Use of a compound antagonist of ESM-1 protein for producing a medicine for treating cancer
    Patent number: 7306797
    Abstract: Use of an antagonist compound of protein ESM-1 for the production of a drug for the treatment of a cancer.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: December 11, 2007
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Philippe Lassalle, David Bechard, André-Bernard Tonnel
  • Use of a compound antagonist of esm-1 protein for producing a medicine for treating cancer
    Publication number: 20040234526
    Abstract: Use of an antagonist compound of protein ESM-1 for the production of a drug for the treatment of a cancer.
    Type: Application
    Filed: April 26, 2004
    Publication date: November 25, 2004
    Inventors: Philippe Lassalle, David Bechard, Andre-Bernard Tonnel
  • Kit and method for detecting the esm-1 protein
    Publication number: 20040063164
    Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising:
    Type: Application
    Filed: October 21, 2003
    Publication date: April 1, 2004
    Inventors: Philippe Lassalle, David Bechard, Andre-Bernard Tonnel